Shaare Zedek Medical Center clinical trial pipeline

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

1. Notable

   Vyxeos for Induction of Low- or Intermediate-risk

   Primary endpoint(s) modified

   Shaare Zedek Medical Center·Phase 2· NCT05599360· Registry history of NCT05599360 on ClinicalTrials.gov (opens the registry)

   Updated Oct 8, 2026

2. Notable

   Patients Between the Ages of 12 Months to 21 Years With…Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

   Recruitment opened

   Shaare Zedek Medical Center·Phase 2· NCT07537400· Registry history of NCT07537400 on ClinicalTrials.gov (opens the registry)

   Updated Sep 17, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.